Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 10/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985372 | 1.00 | OGA (0.42) | OGAAOC3KDM4EOPRM1OPRD1 | |
| SCHEMBL5545464 | 0.96 | AOC3 (0.38) | OGAAOC3 | |
| SCHEMBL5547038 | 0.96 | AOC3 (0.38) | OGAAOC3 | |
| SCHEMBL4985674 | 0.92 | OGA (0.39) | OGAAOC3KDM4EOPRM1OPRD1 | |
| SCHEMBL4984550 | 0.92 | OGA (0.39) | OGAAOC3KDM4EOPRM1OPRD1 | |
| SCHEMBL4984491 | 0.92 | OGA (0.40) | OGAAOC3 | |
| SCHEMBL5551601 | 0.87 | AOC3 (0.37) | OGAAOC3 | |
| SCHEMBL5551593 | 0.87 | AOC3 (0.37) | OGAAOC3 | |
| SCHEMBL4874830 | 0.86 | OGA (0.45) | OGAAOC3KDM4EOPRM1OPRD1 | |
| SCHEMBL4870871 | 0.86 | OGA (0.45) | OGAAOC3KDM4EOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | OGA 1488/4885AOC3 202/4885KDM4E 3439/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | OGA 990/4885AOC3 85/4885KDM4E 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.